Lexicon Pharmaceuticals Prices $94.6M Public Offering and Private Placement
LXRX has more than doubled off its 52-week low of $0.284.
Summary
Lexicon Pharmaceuticals announced the pricing of its $94.6 million public offering and concurrent private placement, with its largest shareholder participating significantly.
Key Events · Financing and Capital Events · LXRX
-
Offering Priced
Lexicon priced its public offering of 32,000,000 common shares at $1.30 per share, expecting gross proceeds of $41.6 million.
-
Concurrent Private Placement
A concurrent private placement to Invus, L.P., Lexicon's largest stockholder, will generate approximately $53.0 million through the sale of common stock and convertible preferred stock.
-
Total Capital Raise
The combined public offering and private placement are expected to generate total gross proceeds of approximately $94.6 million.
-
Use of Proceeds
Net proceeds are earmarked for continued research and development of drug candidates, working capital, and general corporate purposes.
Analysis · LXRX · Life Sciences
This filing finalizes the terms and pricing of the capital raise initiated yesterday, securing approximately $94.6 million in gross proceeds. The offering, priced at $1.30 per share, includes a public offering and a concurrent private placement to Invus, L.P., Lexicon's largest stockholder. This substantial capital infusion is intended to fund continued research and development of drug candidates and for general corporate purposes. While dilutive, the successful completion of this financing, particularly with strong insider participation, provides critical funding for Lexicon's operations and pipeline advancement.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 35.6% of the 1100 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LXRX was trading at $1.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $523.3M. The 52-week trading range was $0.28 to $1.83. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.